Rimon Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
Rimon Therapeutics set out to discover polymers that would achieve a therapeutic effect without acting like drugs; that is, they would act locally, wouldn't be metabolized, and wouldn't be soluble. The company has initially focused its product development efforts on wound healing, with two technologies, polymer beads that induce angiogenesis, and a polymer that sequesters matrix metalloproteinases.
You may also be interested in...
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.